Project Grant R43CA302053
Award Date
6/20/25
Completion Date
5/31/26
Dollars Obligated
$365K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Pensilvania, EE. UU.
Similar Awards
The National Cancer Institute (NCI) awarded a $436,472 R21 project grant to Cedars-Sinai Medical Center under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The objective is to investigate the performance of novel circulating biomarker digital scores for evaluating treatment response in hepatocellular carcinoma (HCC) patients. The research leverages two technologies - an HCC extracellular vesicle digital scoring assay and the GALAD serum protein-based scoring system - to...
The National Cancer Institute (NCI) awarded a $1,280,908 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Exai Bio Inc., a small disadvantaged business in Palo Alto, California. The grant supports the development of a novel assay and artificial intelligence (AI) model for early detection of non-small cell lung cancer (NSCLC) and predicting its subtypes using orphan non-coding RNA (oncRNA) biomarkers. The goal is to create a liquid biopsy-based diagnostic...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The Regents of the University of California, San Francisco (UCSF) totaling $679,188. The grant will fund the development of liquid biopsy tests using artificial intelligence-assisted, morphology-based isolation of tumor cells from malignant effusions to evaluate known actionable breast cancer biomarkers and discover new predictive molecular and morphology-based...
This federal Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $399,112 to Imvaria Inc. to develop a fully automated, AI-powered digital biopsy tool for the non-invasive analysis of suspicious pulmonary nodules from CT scans. The project aims to build and validate a two-stage AI model that can accurately identify and classify pulmonary nodules by risk of malignancy, with a target performance of at least 95% area...
The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded Loyola University of Chicago a $461,844 project grant titled "Hyperpolarized 13C Metabolic Imaging of Tumorigenesis in the Liver". The objective is to use novel hyperpolarized 13C probes to image glycolysis, a critical pathway in hepatocellular carcinoma (HCC) development, and establish in vivo imaging biomarkers to assess altered liver metabolism during HCC progression. The project aims to synthesize a...
This Project Grant award of $580,238 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) will support research to develop novel immune-based blood biomarkers for early detection of hepatocellular carcinoma (HCC) in Hispanic individuals with chronic hepatitis B virus (HBV) infection. The research aims to: 1) determine if novel immune signatures in the serum of HBV-infected HCC patients show differential expression compared to controls; 2) validate...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $399,966 to Cloverleaf Bio, Inc. to advance the pre-clinical development of a novel therapeutic approach for treating hepatocellular carcinoma (HCC), the most common form of liver cancer. The research aims to develop engineered transfer RNAs (tRNAs) containing the chemotherapeutic agent 5-fluorouracil (5-FU) that can irreversibly inhibit multiple tRNA-modifying enzymes, a vulnerability of...
This federal Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, provides $592,027 to Northwestern University to develop and validate a point-of-care molecular diagnostic test for active hepatitis C virus (HCV) infection. The project aims to create a portable, low-cost device that can rapidly diagnose active HCV by detecting viral RNA, eliminating the need for two-step serologic and laboratory-based...
This $700,611 Project Grant, awarded on March 11, 2025 by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, supports a practical randomized controlled trial (RCT) of artificial intelligence (AI) for melanoma diagnosis at Memorial Sloan Kettering Cancer Center (MSK) and Stanford University (SU). The goal is to determine the potential benefits and barriers to clinical adoption of AI-assisted dermoscopy, and to evaluate the impact on the...
This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...